Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2013

View Archived Issues

Scientists at Tangrun Pharmaceuticals synthesize new HCV protease inhibitors

Takara Bio files gene therapy IND with Korean agency

EMA recommends approval of Sanofi Pasteur pediatric vaccine

Ignyta enters collaboration with Leiden University Medical Center

Nanologica to develop nanotechnology drugs with Russian biotech company

Antisense Pharma revises development strategy for anticancer candidate

CBK-201352 shows potent trypanotoxic activity in vitro and in vivo

Arrhythmogenic right ventricular dysplasia model established in vitro

Merck KGaA patents new LPA2 receptor antagonists

Novel agents for tuberculosis and cancer disclosed by CSIR

Researchers at the University of California synthesize novel GABA(A) receptor modulators

Japanese group discloses new ERRalpha inverse agonists

Novel first-in-class therapies hold promise in phase I for acute allergic reactions

Royalty Pharma proposes to acquire Elan

Mitsubishi Tanabe Pharma seeks additional indication for Tenelia in Japan

Shionogi applies for approval of Predonine in Japan

Isis Pharmaceuticals begins phase II study of ISIS-CRPRx in atrial fibrillation

Psyadon enrolls first patients in phase III study of ecopipam in Lesch-Nyhan disease

Inviragen develops dual-purpose recombinant MVA biodefense vaccine

Lytix Biopharma begins new phase II trial of LTX-109 for impetigo

Amarin files sNDA for Vascepa

United Therapeutics plans first clinical study of Pluristem's PLX-PAD cells in PAH

FDA approves Osphena for the treatment of dyspareunia

Arbovax creates tetravalent dengue virus vaccine

Likely delay to FDA review of Zohydro ER

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...